, adalimumab, infliximab, certolizumab, canakinumab, tocilizumab, sarilumab, and secukinumab) are monoclonal antibodies and have special targets like tumor necrosis factor (TNF)-, interleukin (IL)-6, IL-1, and IL-17 ( Although the above mentioned DMARDs have been quite successful in mitigating RA, it is still an undeniable fact that a significant proportion of patients could experience treatment failure, including nonresponse and limited efficacy ( With the deepening of research and exploration, many molecules are identified to exert important roles and bring novel insights to prevent RA
We believe in treating patients holistically - tackling all aspects of physical as well as mental wellbeing - so that when you leave our clinic, you will be armed with the tools needed to continue on your journey towards lasting healthiness
Some medications available through this service may be compounded drugs, which are customized formulations prepared by a pharmacy
Alternating schedules: some may use TB-500 weekly, BPC-157 daily near injury for a period, then taper